Phase II study of spirogermanium in advanced adenocarcinoma of the prostate: a Southwest Oncology Group Study.
Saiers
J H
JH
Veteran's Administration Medical Center, Albuquerque, NM.
Blumenstein
B
B
Slavik
M
M
Costanzi
J H
JH
Crawford
E D
ED
D000230:Adenocarcinoma / Q000188:drug therapy*; D004341:Drug Evaluation; D006801:Humans; D008297:Male; D009942:Organometallic Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013141:Spiro Compounds / Q000009:adverse effects / Q000627:therapeutic use*
D009942:Organometallic Compounds; D013141:Spiro Compounds; C026818:spirogermanium